Literature DB >> 9674618

The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure.

M S Litwin1, R D Hays, A Fink, P A Ganz, B Leake, R H Brook.   

Abstract

OBJECTIVES: The need for accurate measures of health-related quality of life (HRQOL) in men treated for prostate cancer is of paramount importance because patients may survive for many years after their diagnosis. Hence, interest has increased in choosing treatments that optimize both the quality and quantity of life in patients with this disease. This study sought to develop and evaluate a self-administered, multiitem, disease-specific instrument to capture the health concerns central to the quality of life of men treated for early stage prostate cancer.
METHODS: After focus group analysis and pilot testing, the instrument was tested with a large retrospective, cross-sectional survey. Exploratory factor analysis and multitrait scaling analysis were used to facilitate the formation of six scales containing 20 disease-targeted items that address impairment in the urinary, bowel, and sexual domains. The psychometric properties of the new scales were assessed by measuring test-retest reliability, internal consistency reliability, and construct validity. Performance on the new scales was compared with scores on other established cancer-related health-related quality of life instruments. Two hundred fifty-five long-term survivors of prostate cancer treatment and 273 age-matched and ZIP code-matched comparison subjects without prostate cancer from a large managed care population in California were studied. Mean age was 72.7 years. In addition to the new scales, the RAND 36-Item Health Survey (SF-36) was used as a generic core measure, and a cancer-related health-related quality of life instrument (the Cancer Rehabilitation System-Short Form) was used to provide construct validity.
RESULTS: For the new scales, test-retest reliability ranged from 0.66 to 0.93, and internal consistency ranged from 0.65 to 0.93. Disease-targeted measures of function and bother in the three domains correlated substantially with one another. Scale scores correlated well with related, established scales. Men undergoing prostatectomy or pelvic irradiation demonstrated the expected differences in performance on the disease-specific health-related quality of life scales when compared with each other or with comparison subjects. Age was inversely related to sexual and bowel function.
CONCLUSIONS: The UCLA Prostate Cancer Index performed well in this population of older men with and without prostate cancer. It demonstrated good psychometric properties and appeared to be well understood and easily completed. The high response among patients suggests that these men especially are interested in addressing both the general and disease-specific concerns that impact their daily quality of life.

Entities:  

Mesh:

Year:  1998        PMID: 9674618     DOI: 10.1097/00005650-199807000-00007

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  168 in total

1.  Prediction of erectile function following treatment for prostate cancer.

Authors:  Mehrdad Alemozaffar; Meredith M Regan; Matthew R Cooperberg; John T Wei; Jeff M Michalski; Howard M Sandler; Larry Hembroff; Natalia Sadetsky; Christopher S Saigal; Mark S Litwin; Eric Klein; Adam S Kibel; Daniel A Hamstra; Louis L Pisters; Deborah A Kuban; Irving D Kaplan; David P Wood; Jay Ciezki; Rodney L Dunn; Peter R Carroll; Martin G Sanda
Journal:  JAMA       Date:  2011-09-21       Impact factor: 56.272

2.  The effects of dyadic strength and coping styles on psychological distress in couples faced with prostate cancer.

Authors:  Rajni Banthia; Vanessa L Malcarne; James W Varni; Celine M Ko; Georgia Robins Sadler; Helen L Greenbergs
Journal:  J Behav Med       Date:  2003-02

3.  Variations in the quality of care at radical prostatectomy.

Authors:  Quoc-Dien Trinh; Jesse Sammon; Jay Jhaveri; Maxine Sun; Khurshid R Ghani; Jan Schmitges; Wooju Jeong; James O Peabody; Pierre I Karakiewicz; Mani Menon
Journal:  Ther Adv Urol       Date:  2012-04

4.  Watchful waiting and quality of life among prostate cancer survivors in the Physicians' Health Study.

Authors:  Julie L Kasperzyk; William V Shappley; Stacey A Kenfield; Lorelei A Mucci; Tobias Kurth; Jing Ma; Meir J Stampfer; Martin G Sanda
Journal:  J Urol       Date:  2011-09-23       Impact factor: 7.450

5.  Diabetes mellitus and health-related quality of life in prostate cancer: 5-year results from the Prostate Cancer Outcomes Study.

Authors:  Melissa S Y Thong; Lonneke van de Poll-Franse; Richard M Hoffman; Peter C Albertsen; Ann S Hamilton; Janet L Stanford; David F Penson
Journal:  BJU Int       Date:  2010-11-11       Impact factor: 5.588

6.  Radiation Dose to the Penile Structures and Patient-Reported Sexual Dysfunction in Long-Term Prostate Cancer Survivors.

Authors:  Maria Thor; Caroline E Olsson; Jung Hun Oh; David Alsadius; Niclas Pettersson; Joseph O Deasy; Gunnar Steineck
Journal:  J Sex Med       Date:  2015-11-13       Impact factor: 3.802

7.  Development of the NIH PROMIS ® Sexual Function and Satisfaction measures in patients with cancer.

Authors:  Kathryn E Flynn; Li Lin; Jill M Cyranowski; Bryce B Reeve; Jennifer Barsky Reese; Diana D Jeffery; Ashley Wilder Smith; Laura S Porter; Carrie B Dombeck; Deborah Watkins Bruner; Francis J Keefe; Kevin P Weinfurt
Journal:  J Sex Med       Date:  2013-02       Impact factor: 3.802

8.  The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial.

Authors:  James M Wilson; David P Dearnaley; Isabel Syndikus; Vincent Khoo; Alison Birtle; David Bloomfield; Ananya Choudhury; John Graham; Catherine Ferguson; Zafar Malik; Julian Money-Kyrle; Joe M O'Sullivan; Miguel Panades; Chris Parker; Yvonne Rimmer; Christopher Scrase; John Staffurth; Andrew Stockdale; Clare Cruickshank; Clare Griffin; Emma Hall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-01-09       Impact factor: 7.038

9.  The EORTC Quality of Life Questionnaire for patients with prostate cancer: EORTC QLQ-PR25. Validation study for Spanish patients.

Authors:  J I Arraras; E Villafranca; F Arias de la Vega; P Romero; M Rico; M Vila; G Asín; V Chicata; M A Domínguez; N Lainez; A Manterola; E Martínez; M Martínez
Journal:  Clin Transl Oncol       Date:  2009-03       Impact factor: 3.405

10.  Disclosure of diagnosis and treatment among early stage prostate cancer survivors.

Authors:  Trent Jackson; Kimberly Davis; Lisa Haisfield; David Dawson; John Lynch; James Regan; Arnold Kwart; Barlow Lynch; Kathryn Taylor
Journal:  Patient Educ Couns       Date:  2009-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.